This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

HMG CoA reductase inhibitors

Authoring team

HMG CoA reductase inhibitors (statins) include:

  • simvastatin
  • lovastatin
  • pravastatin
  • cerivastatin - marketing and distribution has been suspended in the UK and in all other countries where gemfibrozil is available because of concerns regarding the risk of rhabdomyolysis when these drugs are co-prescribed (1)
  • fluvastatin
  • atorvastatin
  • rosuvastatin

Actions:

  • inhibition of hydroxymethylglutaryl coenzyme A (HMG CoA) in the liver - the rate limiting step in cholesterol synthesis (approximately 50% of circulating cholesterol is endogenously synthesised, the remainder being derived directly or indirectly from the diet
  • reduction in plasma cholesterol and LDL (statins alter the balance of cholesterol and cholesteryl ester within the hepatocyte and increase the removal of IDL and LDL, and decrease the production of VLDL and LDL)
  • increase in LDL receptors
  • small reduction in plasma triglyceride and VLDL
  • modest increase in HDL (mechanism unknown)

Statins are the most potent drugs available for treating hypercholesterolaemia.

Statins are appropriately prescribed in the evening since the synthesis of cholesterol appears most active overnight (2).

The summary of product characteristics should be consulted before prescribing a particular statin.


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.